Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
Crossref DOI link: https://doi.org/10.1007/s40273-014-0206-2
Published Online: 2014-08-20
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fleeman, Nigel
Bagust, Adrian
Beale, Sophie
Dwan, Kerry
Dickson, Rumona
Proudlove, Chris
Dundar, Yenal
Text and Data Mining valid from 2014-08-20